Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
0.7900 x 100 1.2500 x 21
Pre-market by (Cboe BZX)
1.0900 +0.0100 (+0.93%) 04/11/25 [NASDAQ]
0.7900 x 100 1.2500 x 21
Pre-market 1.0900 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0800
Day High
1.1100
Open 1.1100
Previous Close 1.0800 1.0800
Volume 12,900 12,900
Avg Vol 52,115 52,115
Stochastic %K 19.19% 19.19%
Weighted Alpha -57.01 -57.01
5-Day Change -0.0700 (-6.03%) -0.0700 (-6.03%)
52-Week Range 0.8502 - 3.3900 0.8502 - 3.3900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,672
  • Shares Outstanding, K 26,305
  • Annual Sales, $ 11,980 K
  • Annual Income, $ -25,110 K
  • EBIT $ -30 M
  • EBITDA $ -32 M
  • 60-Month Beta 0.46
  • Price/Sales 2.37
  • Price/Cash Flow N/A
  • Price/Book 1.02

Options Overview Details

View History
  • Implied Volatility 660.12% ( +2.96%)
  • Historical Volatility 40.59%
  • IV Percentile 97%
  • IV Rank 50.83%
  • IV High 1,232.53% on 03/13/25
  • IV Low 68.35% on 07/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 40
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 825
  • Open Int (30-Day) 744

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.40
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -1,750.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +5.83%
on 04/08/25
Period Open: 1.3500
1.3700 -20.44%
on 03/13/25
-0.2600 (-19.26%)
since 03/11/25
3-Month
0.8502 +28.21%
on 02/12/25
Period Open: 0.9758
1.5100 -27.81%
on 03/07/25
+0.1142 (+11.70%)
since 01/10/25
52-Week
0.8502 +28.21%
on 02/12/25
Period Open: 3.3400
3.3900 -67.85%
on 04/12/24
-2.2500 (-67.37%)
since 04/11/24

Most Recent Stories

More News
LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs

LAVA Therapeutics shifts focus to LAVA-1266, discontinues LAVA-1207, and secures $5 million from Johnson & Johnson.Quiver AI SummaryLAVA Therapeutics N.V. has announced a strategic reprioritization of...

LVTX : 1.0900 (+0.93%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 0.0435 (-0.68%)
ONCY : 0.6229 (+24.56%)
ONC.TO : 0.88 (+25.71%)
LVTX : 1.0900 (+0.93%)
MRK : 79.18 (+2.10%)
ABBV : 175.05 (+0.49%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 0.6229 (+24.56%)
ONC.TO : 0.88 (+25.71%)
LVTX : 1.0900 (+0.93%)
MRK : 79.18 (+2.10%)
ABBV : 175.05 (+0.49%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

LVTX : 1.0900 (+0.93%)
SGEN : 228.74 (-0.07%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 228.74 (-0.07%)
LVTX : 1.0900 (+0.93%)
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at...

LVTX : 1.0900 (+0.93%)
LAVA Therapeutics Announces Two Appointments to its Board of Directors

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies...

LVTX : 1.0900 (+0.93%)
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. ...

LVTX : 1.0900 (+0.93%)
LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage...

LVTX : 1.0900 (+0.93%)
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple...

LVTX : 1.0900 (+0.93%)

Business Summary

LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

See More

Key Turning Points

3rd Resistance Point 1.1367
2nd Resistance Point 1.1233
1st Resistance Point 1.1067
Last Price 1.0900
1st Support Level 1.0767
2nd Support Level 1.0633
3rd Support Level 1.0467

See More

52-Week High 3.3900
Fibonacci 61.8% 2.4198
Fibonacci 50% 2.1201
Fibonacci 38.2% 1.8204
Last Price 1.0900
52-Week Low 0.8502

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar